Therapeutics: Dodging anti-angiogenic therapy

p243 | doi:10.1038/nrc784

Genomic instability: Defective division

p244 | doi:10.1038/nrc782

Tumour suppressors: More than meets the eye

p244 | doi:10.1038/nrc783

Oncogenes: Monkey business

p246 | doi:10.1038/nrc791

Genomic instability: Caught short

p246 | doi:10.1038/nrc793

Genetic modelling: Highs and lows of prediction

p247 | doi:10.1038/nrc781

Drug resistance: Unable to resist

p248 | doi:10.1038/nrc785

Diagnostics: Predicting outcome

p248 | doi:10.1038/nrc792

Tumour regression: RAS, the magician

p249 | doi:10.1038/nrc794

Conditional mouse models of sporadic cancer

Jos Jonkers & Anton Berns

p251 | doi:10.1038/nrc777

• Abstract
• Full Text
• PDF (620 KB)

Dissecting tumour pathophysiology using intravital microscopy

Rakesh K. Jain, Lance L. Munn & Dai Fukumura

p266 | doi:10.1038/nrc778

• Abstract
• Full Text
• PDF (384 KB)

Death and anti-death: tumour resistance to apoptosis

Frederik H. Igney & Peter H. Krammer

p277 | doi:10.1038/nrc776

• Abstract
• Full Text
• PDF (282 KB)

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

Livio Trusolino & Paolo M. Comoglio

p289 | doi:10.1038/nrc779

• Abstract
• Full Text
• PDF (2,491 KB)

NF-B in cancer: from innocent bystander to major culprit

Michael Karin, Yixue Cao, Florian R. Greten & Zhi-Wei Li

p301 | doi:10.1038/nrc780

• Abstract
• Full Text
• PDF (1,630 KB)